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scriptive statistics were reported for psychiatrists’ sociodemographic and profes-
sional characteristics. Part-worth utilities were estimated using random effects
logit models, and relative importance values were calculated for the attributes.
RESULTS:Complete datawere available from478 psychiatrists; theirmean agewas
52.1 (9.4 SD) years, and the majority were male (n326; 68.2%) and Caucasian
(n354; 74.1%). The psychiatrists had a mean of 19.0 (9.1 SD) years’ experience
practicing psychiatry. Across all patient profiles, the efficacy attribute consistently
had the highest relative importance (RI): 54.93%. Mode of administration
(RI13.51%) and formulary access (RI11.33%) also contributed notably to the psy-
chiatrists’ medication preferences. Other attributes were of more minor impor-
tance, each with RI values 10%, including onset of action (RI6.95%), dosing fre-
quency (RI: oral6.23%; injection0.94%), safety (RI4.30%), and side effects
(RI1.80%). The RI of medication attributes showed some differences across pa-
tient profiles; mode of administration increased in importance for both types of
nonadherent patients, while formulary access and safety decreased in importance.
CONCLUSIONS: The results of the DCE suggest that efficacy is the most important
factor for psychiatrists’ making medication decisions regarding the treatment of
patients with schizophrenia. The RI of efficacy does not vary by patient profile;
however, the RI of other attributes tends to vary depending on the profile of the
patient being treated.
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OBJECTIVES: Identify attributes of patients with schizophrenia taking oral antip-
sychotics who state preference for monthly injectable antipsychotic therapy.
METHODS: From a 2007-2008 survey of patients self-reporting a schizophrenia
diagnosis (N1083), respondents currently using oral antipsychotics but not inject-
ables (N984) were classified as preferring monthly injectable antipsychotic ther-
apy if they answered “very likely” or “extremely likely” on a 5-point Likert scale to,
“If you could receive your medication once a month as an injection, instead of
having to take daily tablets or liquids, how likely would you be to choose the
injection?” (N268). The comparator group consisted of those who answered “not
at all likely” or “somewhat likely” (N485). Attributes were included in a single
logistic regression model with the dependent variable indicated by the preference
for monthly injectable antipsychotic therapy. Independent variables included de-
mographics, attitudes toward disease management, previous medication and
health care resource use, and self-reported adherence, asmeasured by theMorisky
Medication Adherence Scale (MMAS). RESULTS: Current oral antipsychotic users
classified as having low adherence (MMAS3 or 4) were 1.7 times more likely to
prefer monthly injectable antipsychotic therapy (p0.03) than those more adher-
ent. Respondents aged 35-54 years were 1.8 times more likely to prefer monthly
injectable antipsychotic therapy than respondents 55 years (p0.03). Respon-
dents who stated psychiatric medication was a “very important” or “extremely
important” aspect of their life were 2.0 times more likely to prefer monthly inject-
able antipsychotic therapy (p0.01) than those attaching less importance to their
medication. CONCLUSIONS: In this survey of patients with schizophrenia, those
who viewed their psychiatric medication as important and those who reported
lower adherence were more likely to prefer once-monthly injectable antipsychotic
therapy. These insights into patient attitudes and preferences can help mental
health care professionals effectively engage in shared decision making with their
patients. Support: Janssen Scientific Affairs, LLC.
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OBJECTIVES: Levomilnacipran (1S, 2R-milnacipran) is a potent and selective sero-
tonin and norepinephrine reuptake inhibitor (SNRI) in clinical development for the
treatment ofmajor depressive disorder (MDD). Primary and post hoc analyseswere
conducted on data from a positive Phase III trial (NCT00969709) to evaluate the
functional health and well being of patients with MDD treated with sustained
released (SR) levomilnacipran. METHODS: A double-blind, multicenter, parallel-
group, placebo-controlled, fixed-dose study in patients aged 18-65 years who met
DSM-IV-TR criteria for MDD and Montgomery-Asberg Depression Rating Scale-
Clinician Rated (MADRS-CR) score 30. Study comprised a 1-week single-blind,
placebo lead-in, 8-week double-blind treatment, and 2-week double-blind down-
taper. Patients were randomized to placebo (n175) or once-daily levomilnacipran
(n529) 40 mg, 80 mg, or 120 mg (titrated-up from an initial dose of 20 mg). Func-
tional health and well being were measured using change from baseline toWeek 8
on the SF-36v2 acute (1-week recall) health survey. Individual health dimensions,
and physical (PCS) and mental (MCS) component summary scores were compared
for levomilnacipran and placebo (ITT population) using an ANCOVA model.
RESULTS: Patients in both groups had deficits in mental-health (baseline MCS
scores: (placebo, 17.29.2; levomilnacipran, 18.28.5); baseline PCS scores (PBO:
52.611.1; LVM: 51.111.1) were slightly higher than the population norm. Follow-
ing 8 weeks of treatment, levomilnacipran patients versus placebo demonstrated
significantly greater improvement in MCS (LSMD4.41.36; p.0013) and on sev-
eral individual dimensions (General Health [2.30.69; p.0007], Vitality [2.41.05,
p.0228], Social Functioning [3.11.17; p.0086], Role Emotional [3.11.20;
p.0097], Mental Health [4.31.16; p.0003]. Nonsignificant PCS [-0.20.74;
p.8386] and other dimension score changes were noted. CONCLUSIONS: Levom-
ilnacipran patients experienced statistically significant and clinically meaningful
improvements in functional health and well being as measured by the SF-36 MCS
and associated individual dimensions. Nonsignificant changes were noted for the
PCS and associated individual dimensions. Supported by funding from Forest Lab-
oratories, Inc.
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OBJECTIVES: The current focus on the use of real world data in evaluating out-
comes, drug value and in establishing payer coverage policies requires that data be
collected post regulatory approval. The costs involved in formal late phase com-
mitments and the challenge of getting health care providers to participate in data
collection programs like registries can prove overly burdensome and rate limiting.
The objective of this study is to determine if PROmeasures can be incorporated into
patient support programs to collect data that can demonstrate value and be pre-
sented to payers. METHODS: Many product sponsors establish a no cost and toll
free program to support patients navigate their insurance benefits and obtain ac-
cess to prescribe therapy. A total of 2000 opioid addicted patients were divided into
2 groups; 1000 patients were not aligned with clinical care support to monitor
patient reported outcomes and 1000 that reported outcomes data into the patient
support program. RESULTS: Patients who received support services that allowed
for the collection of PRO’s stayed on treatment longer than those who did not have
access to report outcomes. Patients in the reporting arm stayed on therapy on
average three months longer than the patients who did not report outcomes. Pa-
tients who stayed on therapy longer did not cost payers as much as those who
came off of therapy sooner. CONCLUSIONS: Product sponsor patient support pro-
grams can serve as a valuable tool to support the reporting and collecting of PRO
data. Such programs can contain an opt-in procedure to allow patients access to
PRO tools that can help manage their disease and track treatment outcomes. Such
data can then be analyzed and reported on to demonstrate product value and cost
effectiveness through Budget Impact Modeling (BIM) comparing the cost of care of
those who do not track PRO data vs. those who do not.
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OBJECTIVES: The goal of this study was to examine the impact of physical pain on
depression using longitudinal survey data for general population in the United
States. METHODS: This work employed two rounds of Medical Expenditure Panel
Survey (MEPS) fromyears 2008 and 2009. Depressionwasmeasured by frequency of
feeling depressed over the last 2 weeks, scaled by 0-not at all, 1-several days, 2-
more than half the days, and 3-nearly every day. Physical pain was measured by
severity of pain scaled by 1-not at all, 2-a little bit, 3- moderately, 4-quite a bit, and
5-extremely. People older than 18, who had reported severity of depressed mood
and recent physical pain, marriage status, family size, and highest education de-
greeswere included in the study. Only round 2 and round 4 of the surveywere used
since pain questions were only asked in these two rounds. The final panel con-
tained 21,257 observations, among which 46.32% and 45.34% reported pain limited
normal work in round 2 and round 4 respectively; 28.25% and 27.26% documented
depressedmood in round 2 and 4 respectively. Ordinary Least Squares (OLS), Linear
Mixed Effect Model (LME), generalized linear model (GLM) were used to examine
the impact of pain on depression. RESULTS: Comparedwith GLM and LME, the OLS
estimates were shown upward biased. GLM and LME both suggested that individ-
uals whose physical pain deteriorated to the next level from round 2 to round 4
would present a 0.16 (p0.0001) more depressed mood (based on 0-3 scale) on
average. Individuals perceived better health status,were older, richer,married, and
employed were less depressed. CONCLUSIONS: This work utilized a national rep-
resentative longitudinal data to examine the impact of physical pain on depres-
sion. Severity of pain and some individual characteristics were found significantly
affecting the severity of depression.
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OBJECTIVES: Attention-deficit/hyperactivity disorder (ADHD) is the most common
neurobehavioral disorder characterized by developmentally inappropriate levels
of inattention andhyperactivity. Previous literature suggests that, racial and ethnic
disparities continue to exist for several medical conditions. Some studies have
shown that such differences reduce when difference in family income, health in-
surance and such sociodemographic factors are taken into account. But, it has been
also documented that such differences may accentuate for specific type of disor-
der. Aim of this study was to determine any racial and ethnic differences and
weather such differences can be explained by child’s other health condition and
sociodemographic characteristics.METHODS: A nationally representative sample
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of children aged 5-17 years old was obtained from the Medical Expenditure Panel
Survey (MEPS) for the year 2008.MEPS obtained information fromparents about the
health and sociodemographic characteristics of children. Logistic regression along
with descriptive statistics was performed to explain racial and ethnic disparities
among parent reported ADHD. Also, test for normality of residuals, homoscedas-
ticity, goodness of fit and model specification were performed. All analysis was
performed using STATA 11. RESULTS: Out of 6858 children between ages 5-17
years; parents reported ADHD for 633 (9.23%) children. Out of 6858 children 51%
were female, 34% were whites and 43% had any public insurance. Hispanic (OR
0.45 p0.000) and Black (OR0.77 p0.025) parents were less likely to report ADHD
than whites. Parents were more likely to report ADHD for Boys (OR0.65 p0.000),
children with age more than 10 yrs (OR1.85 p0.000), with private (OR1.37
p0.013) and public insurance (OR1.80 p0.012) and frommetropolitan statistical
area (OR 1.20 p0.116). CONCLUSIONS: There are racial disparities among parent
reported ADHD, whites are more likely to report ADHD than Hispanics and blacks.
These differences continue to exist even after controlling for child’s sociodemo-
graphic characteristics and other health related variables.
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OBJECTIVES: Individuals with bipolar disorder (BD) experience a high degree of
impairment that affects aspects of daily life including autonomy, relationships and
employment. The Wide AmbispectiVE study of the clinical management and bur-
den of bipolar disorder (WAVE-bd) aimed to describe functioning and quality of life
(QoL) in a multinational BD cohort. METHODS: Multinational, multicenter, non-
interventional, cohort study of patients diagnosedwith BD-I or BD-II with1mood
episode in the preceding 12 months (retrospective data collection) followed by a
minimum 9 months’ prospective follow-up. Functioning was measured using the
Functioning Assessment Short Test (FAST) tool (score range: 0-72, higher score
indicates worse functionality, results presented from initial visit). QoL was mea-
sured with the EuroQoL-5D visual analogue scale (VAS) tool (score range: 0-100,
higher score indicates better health), and the EQ-5D Index (score range: 0-1, higher
score indicates better health) at every visit during the study. RESULTS: Overall,
2,896 patients were included in the analysis (1,989 BD-I, 907 BD-II). FAST total
scores (meanSD) for BD-I and BD–II patients, respectively, were 50.117.2 and
48.816.5. QoL fluctuated with disease phase; in BD-I patients the EQ-5D VAS
scores (meanSD) were 71.918.3 in hypomania, 70.418.7 in euthymia, 69.622.8
in mania, 56.518.5 in mixed episodes, and 53.522.0 in depression. In BD-II pa-
tients, EQ-5D VAS scores were 72.118.7 in hypomania, 70.017.8 in euthymia and
54.220.2 in depression. EQ-5D Index scores (meanSD) reflected a similar trend
(BD-I: hypomania 0.700.28, mania 0.670.29, mixed episodes 0.530.28, depres-
sion 0.490.29, euthymia 0.410.27; BD-II: hypomania 0.650.27, depression
0.460.27, euthymia 0.410.26). CONCLUSIONS: Patients with BD-I and BD-II ex-
perienced a high level of functional impairment compared to healthy individuals.
QoL was similar in both BD-I and BD-II, and was lowest in patients experiencing
depressive andmixed episodes, and highest in hypomanic episodes and euthymia.
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OBJECTIVES:Major Depressive Disorder (MDD) has been cited as one of the leading
causes of disabilities worldwide. This analysis seeks to explore the prevalence of
MDD across select geographies and to compare the profile of sufferers.METHODS:
Data were taken from the US, Brazil, and Japan 2011 National Health andWellness
Survey, a cross-sectional Internet-based survey representative of the adult popu-
lation. Patients were classified as having MDD using the Patient Health Question-
naire (PHQ9). Health-related quality of life (HRQoL) was assessed with the SF-12
Health Survey (SF-12v2), and activity impairment was measured with the Work
Productivity andActivity Impairment questionnaire (WPAI). Comparisons between
patient groups were made with chi-square tests for categorical variables and
ANOVA for continuous variables. RESULTS: Prevalence of MDD differs significantly
across geographies, with Brazil having the highest percentage (9.8%, 13.5 M) fol-
lowed by US (7.1%, 16.2 M ) and Japan (4.7%, 5.0 M). In US and Brazil, MDD sufferers
were more likely to be women than non-sufferers and were significantly younger
(ps0.05). Sufferers in US, Brazil, and Japan were more likely to experience insom-
nia/sleep difficulties and anxiety than non-sufferers (p0.05). In each geography,
MDD sufferers had a significantly lower mental QoL compared to the non-sufferer
population, but the association was strongest in Japan (28.5 vs. 31.9 in the US vs.
35.4 in Brazil; p0.05). In US, MDD sufferers reported greater work and activity
impairment (42.0% and 51.3%, respectively vs. 12.2% and 18.2% for non-sufferers,
respectively; ps0.05). In all geographies, MDD sufferers had more ER visits in the
past six months relative to non-sufferers (p0.05) with the highest proportion in
Brazil (35.8%). Hospitalization among MDD sufferers was also highest in Brazil
(15.7%). CONCLUSIONS: Cross-country comparisons of MDD can provide insights
to themagnitude of the problem and assess disease burden among these sufferers.
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OBJECTIVES: The aim of this study was to assess the impact of positive and nega-
tive symptoms and cognitive impairment (CI) on health-related quality of life
(HRQOL), productivity loss and health care resource utilization (HCRU) in European
patients with schizophrenia. METHODS: An analysis of patient and physician-
reported data from the cross-sectional Adelphi Schizophrenia Disease-Specific-
Programme was conducted. Subjects 18 years or older with 4 physician visits in
the past year were selected (n2411). Patient-reported HRQOLwas assessed by the
Quality of Life Enjoyment and SatisfactionQuestionnaire-Short Form (Q-LES-Q-SF),
EQ-5D and EQ-5D Visual Analogue Scale (VAS) and work productivity via the Work
Productivity Activity and Impairment (WPAI). HCRU included number of outpa-
tient, emergency and inpatient visits and length of hospital stay (LOS). Analyses of
outcomes and utilization by level and severity of physician-rated positive, negative
and cognitive symptoms employedmultivariate methods (linear, logistic, negative
binomial, tobit and ordered probit regressions) with a backward selection process.
Age, gender, ethnicity, home circumstances, employment, number of comorbidi-
ties, anxiety, depression, non-drug therapy, substance abuse, obesity and medica-
tion compliance served as covariates. RESULTS: Most patients were older, male,
Caucasian, lived alone or with family and were unemployed. Positive symptoms
(delusions, disordered thoughts) and negative symptoms (blunted affect, social
withdrawal) were reported in 40-50% of the patients. Average severity scores for
positive and negative symptoms were 40 (max. 100, higher scores are more se-
vere). A total of 84% of patients suffered “mild” to “continuous or severe CI”. Mul-
tivariate analysis showed that the presence and severity of negative symptoms
decreased Q-LES-Q-SF and EQ-5D VAS scores. CI severity significantly predicted
HRQOL measures, productivity loss in terms of decreased ability to do regular
activities, outpatient, inpatient visits, LOS and non-drug therapy. CONCLUSIONS:
CI was uniquely associated with patient functioning and HCRU. Pharmacological
and non-pharmacological interventions targeted toward CIs may result in better
functioning and lower HCRU.
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OBJECTIVES: About 121 million people worldwide suffer from depression, and it is
the fourth leading cause of disability, according to the World Health Organization.
Cross-cultural studies have revealed that depressive disorders constitute a public
health problem inmost societies. This study is aimed to assess co-morbidity, qual-
ity of life (QOL), work/productivity loss, andmedical resource utilization in patients
diagnosed with depression in Brazil.METHODS: A total of 12,000 Individuals’ (age
18) self-reported data were collected from 2011 National Health and Wellness
Survey (NHWS) in Brazil.. QOL was measured by the physical component score
(PCS) and mental component score (MCS) of the Short Form-12 (SF-12). Loss of
work/productivity was measured by the validated Work Productivity and Activity
Impairment instrument. Medical resource utilization was measured by healthcare
provider, emergency room visits and hospitalization in the past 6 months.
RESULTS: Of the 12,000 respondents, 1,379 (10.8%) had been diagnosed with de-
pression, predominantly women (67.5%). Highest proportion of depression diag-
nosed patients was found between those 18-34 years old (40.8%). Those diagnosed
with depression reported more co-morbidities (anxiety 77.0%, headache 74.8%,
sleep difficulties 59.1%, insomnia 56.65%, pain 47.2%, migraine 39.6%), lower mean
scores of PCS (46.1 vs. 50.1) and MCS (35.8 vs. 48.3), more emergency room visits
(42.4% vs. 19.3%), and more patients being hospitalized for any medical condition
(19.7% vs. 8.6%) over the past 6months compared to not diagnosedwith depression
group. Furthermore, patients diagnosed with depression reported greater overall
work impairment (36.9% vs. 17.3%) and impairment in daily activity (44.5% vs.
18.3%) compared to patients not diagnosed with depression. All comparisons were
statistically significant at p 0.05. CONCLUSIONS: Results from the Brazil NHWS-
indicate patients diagnosedwith depression suffer from impairment in QOL, work/
productivity loss, greater usage of health care resources and more co-morbidities.
Findings indicate there is an unmet medical need in depressive patients in Brazil.
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OBJECTIVES: To measure the impact of the catastrophic 2008 earthquake in the
Sichuan province of China on HRQOL among survivors.METHODS: The study em-
ployed a two-wave longitudinal study of survivors 8 months and three years after
the earthquake, using a probability cluster sample design stratified according to
three levels of earthquake impact. Twelve shelters out of nine townships were
selected during the first-wave sampling, which included three shelters out of three
severely affected townships, six shelters out of three moderately affected town-
ships, and three shelters out of three mildly affected townships. The study was
restricted to individuals between 16 and 89 years of age. A total of 1617 survivors
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